Ticker
ABCL

Price
11.18
Stock movement up
+0.17 (1.54%)
Company name
Abcellera Biologics Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
3.20B
Ent value
3.13B
Price/Sales
5.30
Price/Book
2.56
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
12.88
Forward P/E
-
PEG
-
EPS growth
-
1 year return
20.47%
3 year return
-
5 year return
-
10 year return
-
Last updated: 2023-02-03

DIVIDENDS

ABCL does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E12.88
Price to OCF13.92
Price to FCF19.99
Price to EBITDA8.47
EV to EBITDA8.28

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales5.30
Price to Book2.56
EV to Sales5.19

FINANCIALS

Per share

Loading...
Per share data
Current share count286.10M
EPS (TTM)0.79
FCF per share (TTM)0.51

Income statement

Loading...
Income statement data
Revenue (TTM)603.21M
Gross profit (TTM)516.44M
Operating income (TTM)335.84M
Net income (TTM)248.36M
EPS (TTM)0.79
EPS (1y forward)-0.45

Margins

Loading...
Margins data
Gross margin (TTM)85.61%
Operating margin (TTM)55.68%
Profit margin (TTM)41.17%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash371.97M
Net receivables105.96M
Total current assets1.05B
Goodwill47.81M
Intangible assets142.55M
Property, plant and equipment0.00
Total assets1.55B
Accounts payable9.32M
Short/Current long term debt76.11M
Total current liabilities106.05M
Total liabilities302.24M
Shareholder's equity1.25B
Net tangible assets1.06B

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)229.74M
Capital expenditures (TTM)69.76M
Free cash flow (TTM)159.98M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity19.87%
Return on Assets16.00%
Return on Invested Capital19.79%
Cash Return on Invested Capital12.75%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open10.83
Daily high11.38
Daily low10.73
Daily Volume1.24M
All-time high53.20
1y analyst estimate29.20
Beta-0.24
EPS (TTM)0.79
Dividend per share-
Ex-div date-
Next earnings date21 Feb 2023

Downside potential

Loading...
Downside potential data
ABCLS&P500
Current price drop from All-time high-78.98%-13.68%
Highest price drop-89.25%-56.47%
Date of highest drop11 May 20229 Mar 2009
Avg drop from high-66.14%-11.49%
Avg time to new high108 days13 days
Max time to new high507 days1805 days
COMPANY DETAILS
ABCL (Abcellera Biologics Inc) company logo
Marketcap
3.20B
Marketcap category
Mid-cap
Description
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Employees
475
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
VANCOUVER, British Columbia, February 01, 2023--AbCellera to Present at the SVB Securities Global Biopharma Conference on February 15, 2023
February 1, 2023
VANCOUVER, British Columbia, January 24, 2023--AbCellera to Report Full Year 2022 Financial Results on February 21, 2023
January 24, 2023
Investors need to pay close attention to AbCellera (ABCL) stock based on the movements in the options market lately.
January 24, 2023
AbCellera Biologics saw a positive improvement to its Relative Strength (RS) Rating on Monday, rising from 77 to 81. When looking for the best stocks to buy and watch, keep a close on eye on relative...
January 23, 2023
VANCOUVER, British Columbia, January 20, 2023--AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent
January 20, 2023
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
January 19, 2023
Pliant Therapeutics, Inc. (PLRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in ...
January 12, 2023
It is hard to get excited after looking at AbCellera Biologics' (NASDAQ:ABCL) recent performance, when its stock has...
January 5, 2023
VANCOUVER, British Columbia, January 04, 2023--AbCellera to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023
January 4, 2023
Those following along with AbCellera Biologics Inc. ( NASDAQ:ABCL ) will no doubt be intrigued by the recent purchase...
December 22, 2022
Next page